Although the previous reports of use of IL-6 blockers to treat CRS have shown mixed results, recent clinical data for α-IL-6 and α-IL-6R mAbs have shown early promise in human trials for treatment of severe influenza and corona virus infections (Gritti et al., 2020; Xu et al., 2020). This evidence concerns the gene IL6R and influenza.